David D. Hurd

10.2k total citations
159 papers, 4.8k citations indexed

About

David D. Hurd is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David D. Hurd has authored 159 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 57 papers in Oncology and 41 papers in Pathology and Forensic Medicine. Recurrent topics in David D. Hurd's work include Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and Hematopoietic Stem Cell Transplantation (34 papers). David D. Hurd is often cited by papers focused on Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and Hematopoietic Stem Cell Transplantation (34 papers). David D. Hurd collaborates with scholars based in United States, Canada and Germany. David D. Hurd's co-authors include Philip B. McGlave, Hillard M. Lazarus, Clara D. Bloomfield, B. A. Peterson, Anne I. Goldman, Norma K.C. Ramsay, John H. Kersey, William G. Woods, Tucker W. LeBien and Peter A. Cassileth and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

David D. Hurd

157 papers receiving 4.7k citations

Peers

Countries citing papers authored by David D. Hurd

Since Specialization

Citations

This map shows the geographic impact of David D. Hurd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Hurd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Hurd more than expected).

Fields of papers citing papers by David D. Hurd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Hurd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Hurd. The network helps show where David D. Hurd may publish in the future.

Co-authorship network of co-authors of David D. Hurd

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Hurd. A scholar is included among the top collaborators of David D. Hurd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Hurd. David D. Hurd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 2023 ·HemaSphere ·Katja Weisel, Anita D’Souza, David D. Hurd, Peter M. Voorhees, Raphael Teipel, Alfred Chung, Cesar Rodriguez, (unknown), Neha Korde, Hana Safah, Orlando F. Bueno, (unknown), (unknown), (unknown), Jeremy A. Ross, Shane Lee, Ziyi Jin, (unknown), Shaji Kumar, Ravi Vij	1
2	Development and Implementation of Outpatient CAR-T Program at the Wake Forest Baptist Comprehensive Cancer Center 2021 ·Transplantation and Cellular Therapy ·Rakhee Vaidya, (unknown), Cesar Rodriguez, David D. Hurd, Dianna S. Howard, LeAnne Kennedy, (unknown), (unknown), (unknown), (unknown)	1
3	A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia 2018 ·Clinical Cancer Research ·Timothy S. Pardee, Rebecca G. Anderson, (unknown), Scott Isom, (unknown), Lance D. Miller, Jeff W. Chou, Guangxu Jin, Wei Zhang, Leslie R. Ellis, Dmitriy Berenzon, Dianna S. Howard, David D. Hurd, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell	80
4	Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106 2015 ·The Journal of Community and Supportive Oncology ·Kathryn M. Greven, L. Douglas Case, Lawrence R. Nycum, Patricia J. Zekan, David D. Hurd, Ernie Balcueva, Glenn Mills, Robin Zoň, Patrick J. Flynn, (unknown), Edward Shaw, Glenn J. Lesser, Michelle J. Naughton	4
5	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies 2014 ·Clinical Cancer Research ·Timothy S. Pardee, King Lee, John Luddy, (unknown), Robert M. Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David D. Hurd, Leslie R. Ellis, (unknown), Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell	91
6	Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation 2010 ·Annals of Oncology ·Sergio Giralt, Kenneth F. Mangan, Richard T. Maziarz, Joseph Bubalo, Roy Beveridge, David D. Hurd, Floralyn Mendoza, (unknown), (unknown), Michael W. Schuster	30
7	Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691 2009 ·Leukemia & lymphoma ·Sonali M. Smith, (unknown), Bruce D. Cheson, George P. Canellos, Gina R. Petroni, Martin M. Oken, David B. Duggan, David D. Hurd, Jon P. Gockerman, Barbara A. Parker, Josef T. Prchal, B. A. Peterson, (unknown)	5
8	The transplant iron score as a predictor of stem cell transplant survival 2009 ·Journal of Hematology & Oncology ·(unknown), (unknown), (unknown), David D. Hurd, Gregory J. Pomper, (unknown), (unknown), James Lovato, Suzy V. Torti, Frank M. Torti, István Molnár	31
9	Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis 2007 ·Michael W. Schuster, E. Anaissie, David D. Hurd, Jack W. Singer, James R. Mason, James McCarty, (unknown), Richard T. Maziarz, Yuan‐Di C. Halvorsen, (unknown), William F. Hahne	2
10	Copper deficiency causes reversible myelodysplasia 2007 ·American Journal of Hematology ·(unknown), Yi‐Kong Keung, Mohan C. Thakuri, (unknown), David D. Hurd, John D. Owen, István Molnár	59
11	Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease 2005 ·Bone Marrow Transplantation ·G de Lissovoy, David D. Hurd, (unknown), P Beatty, Marian Ewell, (unknown), Nancy A. Kernan, Saul Yanovich, Daniel J. Weisdorf	9
12	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy 2005 ·Cancer ·Jeffrey Peppercorn, James E. Herndon, Alice B. Kornblith, William P. Peters, Tim A. Ahles, James J. Vredenburgh, Gary N. Schwartz, Elizabeth J. Shpall, David D. Hurd, Jimmie C. Holland, Eric P. Winer, (unknown)	26
13	Use of Fluorescence In Situ Hybridization to Detect Minimal Residual Disease in Hematopoietic Stem Cell Assays from Peripheral Blood Stem Cells of 2 Patients with Trisomy 8 Acute Myeloid Leukemia 2004 ·Stem Cells and Development ·(unknown), Julia M. Cruz, Kenneth W. Zamkoff, David D. Hurd, Mark J. Pettenati	2
14	Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine 2003 ·Cancer ·Ted P. Szatrowski, Richard K. Dodge, (unknown), Carol A. Westbrook, Stanley R. Frankel, Jeffrey Sklar, Carleton C. Stewart, David D. Hurd, Jonathan E. Kolitz, E Vélez-García, Richard M. Stone, Clara D. Bloomfield, Charles A. Schiffer, Richard A. Larson	43
15	Salvage Therapy for Recurrent and Refractory Ovarian Cancer with High-Dose Chemotherapy and Autologous Bone Marrow Support: A Gynecologic Oncology Group Pilot Study 1994 ·Gynecologic Oncology ·E. Randolph Broun, Jerome L. Belinson, Jonathan S. Berek, David E. McIntosh, David D. Hurd, Harrison Ball, Stephen D. Williams	15
16	Trisomy 5 as the sole abnormality in acute lymphoblastic leukemia 1994 ·Cancer Genetics and Cytogenetics ·P. Nagesh Rao, David H. Buss, Sue A. Brown, Michael O’Connor, David D. Hurd, Mark J. Pettenati	8
17	Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission 1990 ·International Journal of Radiation OncologyBiologyPhysics ·Tae Hyong Kim, Philip B. McGlave, Norma K.C. Ramsay, William G. Woods, Bruce Bostrom, Gregory M. Vercellotti, David D. Hurd, William Krivit, Mark E. Nesbit, Robert J. Haake, (unknown), John H. Kersey	43
18	Allogeneic and Autologous Bone Marrow Transplantation for Acute Lymphoblastic Leukemia 1990 ·Hämatologie und Bluttransfusion ·Daniel Weisdorf, N. K. C. Ramsay, Tucker W. LeBien, William C. Woods, (unknown), Mark Nesbit, Daniel A. Vallera, Fatih M. Uckun, Anne I. Goldman, (unknown), P. B. Mcglave, David D. Hurd, R Haake, John Kersey	4
19	Invasive scopulariopsis in the immunocompromised host 1987 ·The American Journal of Medicine ·Joseph P. Neglia, David D. Hurd, Patricia Ferrieri, Dale C. Snover	53
20	Kidnap at Kiunga 1965 ·David D. Hurd	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact